The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors.
Cardio-oncology
Cardio-toxicity
High sensitivity
Immune checkpoint inhibitor
Troponin
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
10
08
2022
accepted:
13
10
2022
pubmed:
28
10
2022
medline:
14
3
2023
entrez:
27
10
2022
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer; however, at the potential cost of serious adverse events including cardiac injury. To assess the baseline and longitudinal changes in high sensitivity-Troponin (hs-Tn) in patients treated with pembrolizumab as a potential predictor for the development of major adverse cardiac events (MACE) and survival. We performed a retrospective analysis of cancer patients treated with pembrolizumab at our center. All participants had baseline measurements of hs-TnI prior to initiation of pembrolizumab (T1), with half of the patients performing follow-up measurements at their second encounter for therapy introduction (T2). We first evaluated the prevalence of abnormally elevated serum hs-TnI (> 50 nanogram per liter) at T1 and T2. We then evaluated the predictive value of abnormal levels at T1 or T2 in relation to the development of MACE (composite outcomes of myocarditis, acute coronary syndrome, heart failure, venous thromboembolism, cardiovascular hospitalization and cardiovascular mortality) and all-cause mortality. Among 135 patients, the mean age was 72 years, predominantly male (61%). Abnormally elevated hs-TnI at T1 was observed in 7 (5%) patients and emerged as a significant independent predictor for MACE (HR 8.1, 95% CI 1.67-37.4, p = 0.009) and all-cause mortality (HR 5.37, 95% CI 2.1-13.57, p < 0.001). Abnormally elevated hs-TnI at T2 was observed in 8 (11%) patients and emerged as a significant independent predictor for MACE (HR 10.49, 95% CI 1.68-65.5, p = 0.009), but not for mortality (p = 0.200). Abnormally elevated baseline and follow-up hs-TnI served as significant independent predictors for MACE, with an increased risk of development being 8-tenfold. Furthermore, elevated baseline hs-TnI showed a predictive value for all-cause mortality. Central illustration: Novel immune checkpoint inhibitor (ICIs) therapy has been found to revolutionize cancer therapy through increased activation of host immune systems to target and reduce tumor burden, but may come at the cost of serious adverse cardiac events. Identification of early biomarkers for the prediction and detection of these events is necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer; however, at the potential cost of serious adverse events including cardiac injury.
OBJECTIVE
OBJECTIVE
To assess the baseline and longitudinal changes in high sensitivity-Troponin (hs-Tn) in patients treated with pembrolizumab as a potential predictor for the development of major adverse cardiac events (MACE) and survival.
METHODS
METHODS
We performed a retrospective analysis of cancer patients treated with pembrolizumab at our center. All participants had baseline measurements of hs-TnI prior to initiation of pembrolizumab (T1), with half of the patients performing follow-up measurements at their second encounter for therapy introduction (T2). We first evaluated the prevalence of abnormally elevated serum hs-TnI (> 50 nanogram per liter) at T1 and T2. We then evaluated the predictive value of abnormal levels at T1 or T2 in relation to the development of MACE (composite outcomes of myocarditis, acute coronary syndrome, heart failure, venous thromboembolism, cardiovascular hospitalization and cardiovascular mortality) and all-cause mortality.
RESULTS
RESULTS
Among 135 patients, the mean age was 72 years, predominantly male (61%). Abnormally elevated hs-TnI at T1 was observed in 7 (5%) patients and emerged as a significant independent predictor for MACE (HR 8.1, 95% CI 1.67-37.4, p = 0.009) and all-cause mortality (HR 5.37, 95% CI 2.1-13.57, p < 0.001). Abnormally elevated hs-TnI at T2 was observed in 8 (11%) patients and emerged as a significant independent predictor for MACE (HR 10.49, 95% CI 1.68-65.5, p = 0.009), but not for mortality (p = 0.200).
CONCLUSIONS
CONCLUSIONS
Abnormally elevated baseline and follow-up hs-TnI served as significant independent predictors for MACE, with an increased risk of development being 8-tenfold. Furthermore, elevated baseline hs-TnI showed a predictive value for all-cause mortality. Central illustration: Novel immune checkpoint inhibitor (ICIs) therapy has been found to revolutionize cancer therapy through increased activation of host immune systems to target and reduce tumor burden, but may come at the cost of serious adverse cardiac events. Identification of early biomarkers for the prediction and detection of these events is necessary.
Identifiants
pubmed: 36301334
doi: 10.1007/s00392-022-02118-8
pii: 10.1007/s00392-022-02118-8
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Biomarkers
0
Troponin
0
Troponin T
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-418Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Wolchok JD (2015) PD-1 blockers. Cell 162(5):937
doi: 10.1016/j.cell.2015.07.045
pubmed: 26317459
Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(11):1413–1422
doi: 10.1016/S1470-2045(20)30453-8
pubmed: 32979984
Cascone T, William WN Jr, Weissferdt A et al (2021) Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504–514
doi: 10.1038/s41591-020-01224-2
pubmed: 33603241
pmcid: 8818318
Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [published correction appears in Lancet. Lancet 398(10308):1344–1357
Rothlin CV, Ghosh S (2020) Lifting the innate immune barriers to antitumor immunity. J Immunother Cancer 8(1):e000695
doi: 10.1136/jitc-2020-000695
pubmed: 32273348
pmcid: 7254113
Emens LA, Ascierto PA, Darcy PK et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116–129
doi: 10.1016/j.ejca.2017.01.035
pubmed: 28623775
Guo CW, Alexander M, Dib Y et al (2020) A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer 124:15–24
doi: 10.1016/j.ejca.2019.09.009
pubmed: 31707280
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19(9):e447–e458
doi: 10.1016/S1470-2045(18)30457-1
pubmed: 30191849
Liu Y, Wu W (2020) Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. Asia Pac J Clin Oncol 16(4):232–240
doi: 10.1111/ajco.13326
pubmed: 32129935
pmcid: 7496884
Ball S, Ghosh RK, Wongsaengsak S et al (2019) Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week [published correction appears in J Am Coll Cardiol. 2019 Nov 26;74(21):2711–2712]. J Am Coll Cardiol 74(13):1714–1727
Liu S, Chan J, Brinc D et al (2020) Immune checkpoint inhibitor-associated myocarditis with persistent troponin elevation despite abatacept and prolonged immunosuppression. JACC CardioOncol 2(5):800–804 (Published 2020 Dec 15)
doi: 10.1016/j.jaccao.2020.10.013
pubmed: 34396297
pmcid: 8352272
Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933
doi: 10.1016/S0140-6736(18)30533-6
pubmed: 29536852
pmcid: 6668330
van der Linden N, Klinkenberg LJJ, Bekers O et al (2016) Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis. Medicine (Baltimore) 95(52):e5703
doi: 10.1097/MD.0000000000005703
pubmed: 28033267
Cardinale D, Sandri MT (2010) Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53(2):121–129
doi: 10.1016/j.pcad.2010.04.002
pubmed: 20728699
Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36(2):517–522
doi: 10.1016/S0735-1097(00)00748-8
pubmed: 10933366
Lyon A, Lopez-Fernandez T, Couch L et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 00:1–133
Lyon A, Dent S, Stanway S et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22(11):1945–1960
doi: 10.1002/ejhf.1920
pubmed: 32463967
Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764
doi: 10.1016/j.jacc.2018.02.037
pubmed: 29567210
pmcid: 6196725
Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227–3337
doi: 10.1093/eurheartj/ehab484
pubmed: 34458905
Lang RM, Bierig M, Devereux RB et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79–108
doi: 10.1016/j.euje.2005.12.014
pubmed: 16458610
Lehmann LH, Cautela J, Palaskas N et al (2021) Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol 6(11):1329–1337
doi: 10.1001/jamacardio.2021.2241
pubmed: 34232253
Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2021 Mar;22(3):e92]. Lancet Oncol 22(2):198–211
Peleg Hasson S, Arnold J, Merdler I et al (2021) Cancer therapeutics-related cardiac dysfunction in patients treated with immune checkpoint inhibitors: an understudied manifestation. J Immunother 44(5):179–184
doi: 10.1097/CJI.0000000000000371
pubmed: 33950028
Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474–2481
doi: 10.1161/CIRCULATIONAHA.106.635144
pubmed: 17101852
Petricciuolo S, Delle Donne MG, Aimo A, Chella A, De Caterina R (2021) Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. Eur J Clin Investig 51(4):e13400
doi: 10.1111/eci.13400
Waliany S, Neal JW, Reddy S et al (2021) Myocarditis surveillance with high-sensitivity troponin i during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol 3(1):137–139
doi: 10.1016/j.jaccao.2021.01.004
pubmed: 33796869
pmcid: 8009332
Rini BI, Moslehi JJ, Bonaca M et al (2022) Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN Renal 101 trial [published online ahead of print, 2022 Mar 3]. J Clin Oncol JCO2101806